Diepenbeek, Belgium, 14 October 2020 – Cannovex BV (the ‘Company’ or ‘Cannovex), a developer of cannabinoid-based medicines today announces that it has been awarded a EUR 0.5 million development grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship. The grant will run over two years and will support the development of nanofibrous films for transmucosal delivery of cannabinoids.
Diepenbeek, België, 14 oktober 2020 – Cannovex BV (de ‘Vennootschap of ‘Cannovex’), een ontwikkelaar van cannabinoïde gebaseerde geneesmiddelen kondigt vandaag aan dat het een ontwikkelingssteun ontvangt van EUR 0.5 miljoen van VLAIO, het Vlaams Agentschap Innoveren & Ondernemen. De subsidie zal over twee jaren gespreid worden en de ontwikkeling van nanovezel films ondersteunen voor de transmucosale opname van cannabinoïden.
The 4-page article about Cannovex appeared in the edition of Trends Magazine on Thursday 30th April 2020. The article is about how Cannovex will develop new cannabinoid-based medicines with a focus on combating the current opioid crisis. Cannovex CEO, Mr. Steven Peters, shares his vision on the development of cannabinoid-based medicines in Belgium and Europe and how Cannovex will make the difference. Click on the link to read the full-text article (available in PDF) Part 1 Part 2 Available only in Dutch. © Trends www.trends.be
The parliamentary Health Committee almost unanimously adopted a bill facilitating the creation of a cannabis agency, enabling production of the drug for medical purposes. Cannabis will now be able to be prescribed for patients for whom mainstream medicines have proven to be of little or no use. Such a prescription will be done through the creation of a specific agency. Increasingly countries are allowing the use of cannabis for therapeutic ends. The drug in particular provides relief from illnesses such as Multiple Sclerosis, Amyotrophic Lateral Sclerosis, or for those suffering from pains or spasms. The cannabis agency would work under the auspices of the Federal Agency for Medicines. It will be permitted to supply authorizations for future plantations and producers, and will manage cannabis crop harvests. The agency will also ensure the monopoly on cannabis imports and exports, so that the drug is not used for illegal purposes. The agency will make cannabis available for pharmacists and hospitals. On Tuesday, the proposed law received the support of all political groups, except for the N-VA (Nieuw-Vlaamse Alliantie) which abstained. Parliament is yet to fully discuss and understand the legislation in a plenary session. Christopher Vincent The Brussels Times (Source: http://www.brusselstimes.com/belgium/14233/cannabis-agency-adopted-almost-unanimously-by-parliamentary-committee )
The European Parliament is calling for an EU-wide policy for medical cannabis and properly funded scientific research. Several EU countries have legalised the medical use of some form of cannabis or cannabinoids or are considering changes to their legislation. However, the rules on which products are allowed and how they should be used vary widely, although no EU country authorises the smoking or home-growing of cannabis for medical purposes. While the World Health Organization has officially recommended that the cannabis compound cannabidiol (CBD) should not be classified as a controlled substance, there are no EU-wide rules at the moment for either the medical or recreational use of cannabis. What is cannabis? The cannabis plant is made up of more than 480 compounds, including more than 100 cannabinoids, the best known being THC (D9-tetrahydrocannabinol) and cannabidiol (CBD) THC is the main psychoactive and addictive constituent of cannabis; CBD has no intoxicating or addictive properties The medical use of cannabis and cannabinoids can refer to a wide variety of plant-based and synthetic preparations and products Many countries use the Mexican term marijuana to refer to cannabis leaves. The unpollinated female plants are called hashish On 13 February, MEPs adopted a resolution on the…
MEPs will debate ways to address research gaps on medical cannabis with the European Commission, and adopt a resolution on Wednesday. MEPs will quiz the Commission on how the EU could support quality research on cannabis-based medicines and establish standards for non-pharmaceutical medical cannabis to ensure consumer safety. The draft resolution stresses the need for the Commission and national authorities to draw a clear distinction between medical cannabis and other uses of cannabis. It calls on the Commission and member states to address regulatory barriers which burden scientific research and invites them to properly fund research and promote greater knowledge of medical cannabis among medical professionals. Background MEPs believe that there is substantial evidence that cannabis and cannabinoids have therapeutic effects for treating chronic pain in adults, chemotherapy-induced nausea and vomiting, and improve muscle spasticity symptoms in multiple sclerosis. Whilst the WHO has officially recommended that the cannabis compound cannabidiol (CBD) should not be considered a controlled substance, legislation in member states differs widely on the subject of cannabis for medicinal purposes. (Source: http://www.europarl.europa.eu/news/en/agenda/briefing/2019-02-11/10/take-medical-use-of-cannabis-seriously-say-meps )
The Limburg company Rendocan would like to legally produce five tonnes of therapeutic cannabis per year in Kinrooi, not far from the Dutch border. De Tijd et L'Echo are reporting on Friday that to achieve the end, the current legal framework needs to be adapted. A current study by the department for the Minister of Health, Maggie De Block (Open Vld) is looking into the feasibility of the proposals. Rendocan plans to establish the first plantation within the sphere of therapeutic cannabis in continental Europe in Kinrooi, also including a research centre. Primarily, the Limburg company is targeting the German market. Steven Peters, speaking on behalf of Rendocan, explains, “We consider ourselves to be a biotechnology company and, to produce our added value, we are undergoing the development of new seeds.” However, growing therapeutic cannabis for the moment remains an illegal activity in Belgium, and the legal framework must therefore be adapted. The matter is in the process of being considered by the department for the Minister Maggie De Block (Open Vld). The department has issued a statement as follows, “There are several ‘Gordian knots’ still to be untied, and we would prefer not to say more for the moment.” Whilst awaiting the…
The Federal Agency for Medicines and Health Products (FAMHP) has received anapplication to allow the establishment of a large R&D facility to perform large-scale research into medicinal cannabis in the town of Kinrooi in the provence of Limburg. If this research facility can be established, it will generate approximately 500 to 800 new jobs. The suppression of spasticity in MS patients or pain relief to cancer: the impact of medical cannabis in the year 2016 is undisputed. "Still, much more research is absolutely needed," says Joris Vanvinckenroye, founder of Royal Doctors. (continue reading below the picture) (Copyrights: De Standaard / WFA) Vanvinckenroye wants to establish a research facility that needs to figure out how the cannabis plant can be stabilized and optimized to express the perfect THC and CBD levels ratios, so they are suitable for large-scale drug production. The goal is to develop specific strains that are optimized for specific illnesses. If the research facility is coming, it means, according Vanvinckenroye, an investment of 80 million euros and employment of 500 FTE.
Rendocan has entered in a partnership with the University of Hasselt. Various departments (Agricultural and Environmental Sciences, Statistics, Biomedical Sciences, Healthcare, etc.) expressed their intent to form a strategic partnership with Rendocan, to expand their knowledge about the cannabis plant and how it and its components may be used to alliviate symptoms of specific diseases. As such, the partnership was signed by the head of the university, Prof.Dr. Luc De Schepper, and the scope encompasses the entire university and all its departments. Rendocans research facility at the Agropolis Business Park in Kinrooi will be the main interest of the University. Here, the most experienced researchers are provided with a safe and state-of-the-art working environment, to advance the science about cannabis.